COSTA MESA, CA / ACCESSWIRE / June 3, 2015 / NEMUS Bioscience Inc. (NMUS) is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids, designed to alleviate a variety of diseases and symptoms by selectively targeting CB1 and CB2 receptors. NEMUS Bioscience, Inc. will be presenting on the Cannabis Investor Webcast on Thursday, June 4, 2015 at 3:00 PM ET.
"We're excited that NEMUS Bioscience, Inc. has decided to present to our online audience of industry investors, analysts, executives, media, and consumers," said Derwin A. Wallace, Senior V.P. of Investor Webcast. "The online interactive webcast will assist NEMUS Bioscience, Inc. in increasing its awareness and exposure."
The Cannabis Investor Webcast will include presentations from privately-held and publicly-traded industry companies and industry professionals. NEMUS Bioscience, Inc. presentation will be 30-minutes long and followed by 15-minutes of Q&A. The Cannabis Investor Webcast is a great opportunity for the audience to research industry companies without taking time-off from work, paying registration fees and incurring travel-related expenses.
"The Cannabis Investor Webcast is an online interactive platform that will assist us in introducing NEMUS Bioscience, Inc. and its cannabinoid based therapy to industry investors, analysts, executives, media, and consumers," states John Hollister, CEO of NEMUS Bioscience, Inc.
Cannabis investors, analysts, executives, media, and consumers who would like to attend our free online webcast please click on the link http://www.cannawebcast.com/ and visit the Registration Page and to view the recording of the webcast please visit www.youtube.com and search for "Cannabis Investor Webcast" two weeks after presentation.
About NEMUS Bioscience, Inc.
The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabis-based therapeutics for global markets with significant unmet medical needs. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabis-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS's strategy is not limited to the sole use of either natural or synthetic inputs. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.
For more information, visit www.nemusbioscience.com.
Forward Looking Statements
Statements in this document that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "believes," "can," "challenge," "predictable," "will," or the negative of these terms or other comparable terminology. We operate in a rapidly-changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make.
Contact: Investor relations 818-377-7426
SOURCE: Cannabis Investor Webcast